Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 30, Issue 8, 2012, Pages

  Lind, Joline S W ^a   Senan, Suresh ^a   Smit, Egbert F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CORTICOSTEROID; PREDNISOLONE;

ADULT; AGED; ARTICLE; ATELECTASIS; BONE METASTASIS; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DYSPNEA; FATIGUE; FEMALE; FEVER; FORCED VITAL CAPACITY; GRANULATION TISSUE; HOME OXYGEN THERAPY; HUMAN; INOPERABLE CANCER; LARGE CELL CARCINOMA; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG EXAMINATION; LUNG FIBROSIS; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; LUNG SURGERY; LUNG TOXICITY; MALAISE; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION PNEUMONIA; WEIGHT REDUCTION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIATION PNEUMONITIS; RADIOTHERAPY;

EID: 84858857700     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.4552     Document Type: Article

References (18)

1. Cohen MH, Gootenberg J, Keegan P, et al: FDA drug approval summary: Bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12:713-718, 2007 (Pubitemid 47036205)
2. Cohen MH, Gootenberg J, Keegan P, et al: FDA drug approval summary: Bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12:356-361, 2007 (Pubitemid 46556802)
3. Crinò L, Dansin E, Garrido P, et al: Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): A phase 4 study. Lancet Oncol 11:733-740, 2010
4. Senan S, Smit EF: Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 12:465-477, 2007 (Pubitemid 46698724)
5. Koukourakis MI, Giatromanolaki A, Sheldon H, et al: Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: Vasculature-independent radiosensitizing effect of bevacizumab. Clin Cancer Res 15:7069-7076, 2009
6. Spigel DR, Hainsworth JD, Yardley DA, et al: Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 28:43-48, 2010
7. Gore E, Currey A, Choong N: Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy. J Thorac Oncol 4:1590-1591, 2009
8. Senan S, De Ruysscher D, Giraud P, et al: Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 71:139-146, 2004 (Pubitemid 38521181)
9. Mazeron R, Etienne-Mastroianni B, Pérol D, et al: Predictive factors of late radiation fibrosis: A prospective study in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 77:38-43, 2010
10. Senan S, Cardenal F, Vansteenkiste J, et al: A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. Ann Oncol 22:553-558, 2011
11. Albain KS, Swann RS, Rusch VW, et al: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet 374:379-386, 2009
12. Zhao L, Sheldon K, Chen M, et al: The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer 59:232-239, 2008 (Pubitemid 351173403)
13. Vujaskovic Z, Groen HJ: TGF-beta, radiation-induced pulmonary injury and lung cancer. Int J Radiat Biol 76:511-516, 2000 (Pubitemid 30232450)
14. De Jaeger K, Seppenwoolde Y, Kampinga HH, et al: Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58:1378-1387, 2004 (Pubitemid 38438297)
15. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004 (Pubitemid 38524883)
16. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
17. Winkler F, Kozin SV, Tong RT, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563, 2004 (Pubitemid 40017699)
18. Goyal S, Rao MS, Khan A, et al: Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab. Int J Radiat Oncol Biol Phys 79:408-413, 2011 [epub ahead of print on May 6, 2010]